Shah Pritesh 4
4 · NovoCure Ltd · Filed Mar 9, 2022
Insider Transaction Report
Form 4
NovoCure LtdNVCR
Shah Pritesh
Chief Commercial Officer
Transactions
- Sale
Ordinary Shares
2022-03-08$70.10/sh−2,481$173,918→ 81,908 total - Sale
Ordinary Shares
2022-03-07$69.55/sh−5,294$368,198→ 84,389 total
Footnotes (1)
- [F1]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.